Organization | National Research Foundation of Korea

National Research Foundation of Korea Report issue

Government Phase 2 Phase 4

Founded: Daejeon Korea, Republic of (2009)

Organization Overview

First Clinical Trial

2015

NCT03547219

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

National Research Foundation of Korea

Active Ingredients

Drugs in Phase 4 Trials (3)

gadoxetate disodium (eovist) (1 trial)

indocyanine green (ic-green) (1 trial)

sodium chloride (2 trials)

Drugs in Phase 2 Trials (2)

thiamine (1 trial)

vitamin c (1 trial)

Drugs in Other Trials (4)

acetylsalicylic acid (aspirin) (1 trial)

clopidogrel (plavix) (1 trial)

escitalopram (lexapro) (1 trial)

ticagrelor (brilinta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Fibrosis (Phase 4)

Hyponatremia (Phase 4)

Shock (Phase 2)

Shock, Septic (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 5
# of Trial APIs: 9